Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2803

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

Blood (2025) 146 (12): 1440–1449.

https://doi.org/10.1182/blood.2024027902

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Blood (2025) 146 (12): 1476–1492.

https://doi.org/10.1182/blood.2024024719

Published: 2025

Includes: Supplemental data

Journal Articles

Drug development in MZL: caring for the forgotten child

Catherine Thieblemont, Sylvain Carras, Côme Bommier

Blood blood.2024028270.

https://doi.org/10.1182/blood.2024028270

Published: 2025

Journal Articles

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Blood (2025) 146 (11): 1286–1299.

https://doi.org/10.1182/blood.2024026340

Published: 2025

Includes: Supplemental data

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood (2025) 146 (11): 1300–1313.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Blood (2025) 146 (11): 1314–1330.

https://doi.org/10.1182/blood.2025028560

Published: 2025

Includes: Supplemental data

Journal Articles

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

Blood blood.2025028441.

https://doi.org/10.1182/blood.2025028441

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Blood (2025) 146 (10): 1225–1238.

https://doi.org/10.1182/blood.2024028164

Published: 2025

Includes: Supplemental data

Journal Articles

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Ilaria Romano, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Eleonora Calabretta, Stephane Chauvie, Francesco Corrado, Stefania Crisci, Marco Cuzzocrea, Rosaria De Filippi, Bernhard Gerber, Michał Kurlapski, Luigi Maria Larocca, Elisabetta Merlo, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Alexandar Tzankov, Carmelo Carlo-Stella, Gianluca Gaidano, Luca Ceriani, Emanuele Zucca, Davide Rossi

Blood (2025) 146 (10): 1207–1224.

https://doi.org/10.1182/blood.2024027355

Published: 2025

Includes: Supplemental data

Journal Articles

Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis

Nirija Ranjit Anderson, Sharmila Dorbala, Peter Mollee

Blood (2025) 146 (10): 1157–1162.

https://doi.org/10.1182/blood.2024026386

Published: 2025

Journal Articles

The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma

Dylan James Tatterton, Maddy L Newby, Joel D Allen, Benjamin J Sale, Giorgia Chiodin, Patrick J Duriez, John Butler, Katy J McCann, David W. Scott, Ryan D Morin, Kostiantyn Dreval, Andrew J Davies, Dean Bryant, Max Crispin, Francesco Forconi

Blood blood.2025029163.

https://doi.org/10.1182/blood.2025029163

Published: 2025

Includes: Supplemental data

Journal Articles

Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma

Ipsita Pal, Anuradha Illendula, Andrea Megan Joyner, John Sanil Manavalan, Tess M Deddens, Ariana Sabzevari, Deepthi P Damera, Samir Zuberi, Enrica Marchi, Todd E Fox, Marya Dunlap Brown, Kallesh Danappa Jayappa, Jihane Khalife, Jeffrey W. Craig, Thomas P Loughran, David J. Feith, Owen A. O'Connor

Blood blood.2024027997.

https://doi.org/10.1182/blood.2024027997

Published: 2025

Includes: Supplemental data

Journal Articles

Immune alterations in myeloma evolution and outcomes: quo vadis?

Madhav V. Dhodapkar, Bruno Paiva

Blood (2025) 146 (9): 1041–1050.

https://doi.org/10.1182/blood.2024026227

Published: 2025

Journal Articles

Lineage switch from KMT2A -rearranged congenital B-ALL to AML in an infant: a genomic perspective

Rohan Kodgule, Kiran R. Vij

Blood (2025) 146 (9): 1142.

https://doi.org/10.1182/blood.2025029472

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (9): 1051–1064.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood blood.2025028899.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Erin W Meermeier, Kirsten Pfeffer, Caleb K Stein, Meaghen Sharik, Megan Tien Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu, Peter Leif Bergsagel, Marta Chesi

Blood blood.2025029215.

https://doi.org/10.1182/blood.2025029215

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood (2025) 146 (8): 964–970.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Drug development in MZL: caring for the forgotten child

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis

The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma

Nanoromidepsin, a Polymer Nanoparticle of the HDAC Inhibitor, Improves Safety and Efficacy in Models of T-cell Lymphoma

Immune alterations in myeloma evolution and outcomes: quo vadis?

Lineage switch from KMT2A -rearranged congenital B-ALL to AML in an infant: a genomic perspective

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only